BioBridge Foundation launches the UK & Northern Europe educational season 2026-2027

Focus on scientific exchange, selective clinical education and evidence-aware implementation

BioBridge Foundation is introducing a UK & Northern Europe educational season from September 2026 to February 2027.

The programme redirects the scientific work and relationships developed for the BioBridge London Symposium into a series of smaller, more focused activities with clear educational purpose and closer faculty engagement.

Explore the educational season events

• 17 September 2026 : BioBridge London Expert Dinner Forum

• 18 September 2026 : BioBridge London Clinical Pathway Day

• 9 October 2026 : BioBridge Kaunas Clinical Training Day

• 29-30 October 2026 : BioBridge London Dermal & Women’s Health Forum and Clinical Day

• 26-27 November 2026 : BioBridge London Men’s Health Forum and Clinical Day

• 12 February 2027 | Vilnius: BioBridge Baltic Day 2027

 

Explore

This new format offers several advantages:

Closer interaction with faculty

More opportunities for case-based discussion and mentoring

Evidence-based approaches in sexual medicine

Greater focus on practical topics, including patient pathways, clinical decision-making and responsible implementation

Future innovations in andrology and gynaecology

A more interactive learning environment with direct access to expert perspectives

Future innovations in andrology and gynaecology

Disclaimer: Regenlab is the BioBridge Foundation technology sponsor.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

More

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

More

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

More

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

More

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

CM-OA
CM-Skin

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

More

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

More

RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.

More

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

More

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

More

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.

More